Business
University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation
Agreement builds on long-established partnership and demonstrates the strength and importance of industry/academic scientific collaborationsCharlottesville, VA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The University of Virginia (UVA) today announced the signing of a Master Research Collaboration Agreement with AstraZeneca designed to expedite pre-clinical research partnerships between the global biopharmaceutical company and UVA’s schools and departments. The agreement streamlines processes and enable
About this update from Astrazeneca Plc
[{"type":"text","content":"Agreement builds on long-established partnership and demonstrates the strength and importance of industry/academic scientific collaborations","length":140,"tagName":"p"},{"type":"text","content":"Charlottesville, VA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The University of Virginia (UVA) today announced the signing of a Master Research Collaboration Agreement with AstraZeneca designed to expedite pre-clinical research partnerships between the global biopharmaceutical company and UVA’s schools and departments. The agreement streamlines processes and enables AstraZeneca’s research and development teams to work more effectively and efficiently across UVA’s breadth of scientific expertise, infrastructure and innovation ecosystem.","length":534,"tagName":"p"},{"type":"text","content":"The agreement will provide a framework that is designed to enhance the pace of discovery and translational research in areas spanning oncology, immunology, cardiovascular, metabolism and infectious disease research. The agreement establishes standardized terms and operational pathways for pre-clinical projects, aimed at reducing time-to-launch for collaborative studies and facilitating cross-disciplinary engagement.","length":419,"tagName":"p"},{"type":"text","content":"“This master agreement reflects UVA’s commitment to catalyzing breakthrough science and translating ideas into impact,” said Scott Beardsley, UVA’s President. “By creating a seamless way for AstraZeneca’s teams to collaborate across our academic enterprise, we are opening doors for faculty, trainees and research staff to accelerate discovery and deliver tangible benefits to patients and communities.”","length":403,"tagName":"p"},{"type":"text","content":"The master agreement will reduce administrative hurdles, align compliance and data stewardship standards, and support efficient contracting across departments and institutes.","length":174,"tagName":"p"},{"type":"text","content":"“This is a significant step forward for UVA’s research enterprise,” said Lori L. McMahon, UVA Vice President for Research. “Our investigators are at the forefront of fundamental and translational science. With this master agreement, we can move faster, work smarter, and ensure that promising ideas are rigorously advanced toward clinical relevance. It’s a win for our faculty, our trainees and—most importantly—the pati...